• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

PEPTONIC Medical AB: VagiVital® AL for amniotic leakage detection now commercially available

VagiVital® AL is a patented self-test to detect amniotic fluid leakage. VagiVital® AL in short;
  • A unique patented technology designed to detect amniotic leakage
  • Comes in the form of a panty liner where the patented technology is embedded
  • Can distinguish between amniotic fluid and urine with 97% accuracy
During later stages of pregnancy, many women suffer from diffuse leakage, where it is very difficult to know whether the leakage consists of urine or amniotic fluid. The risk of an undiagnosed amniotic fluid discharge is ascending infections from the vagina into the uterine cavity, which in turn can lead to complications for both mother and child (severe infection in the uterus or placenta, fever, sepsis in the mother, pneumonia in the child). In 47% of cases, doctors are unsure of the diagnosis of hydrocephalus based only on clinical examination and the patient's input.
  •  With VagiVital® AL, we provide pregnant women and healthcare providers with a unique, clinically proven and easy-to-use method that has no equivalent on the market today, says Erik Sundquist, CEO at Peptonic Medical.
  • The method used in Sweden to rule out suspicion of, or confirm hydrocephalus is a vaginal examination with sterile instruments. It is time-consuming, takes up space at specialist maternity care and can mean unnecessary travel for pregnant women in sparsely populated areas. VagiVital® AL is easier to use, can be sent home with the pregnant woman or performed at the clinic and is therefore a more user-friendly product in outpatient care, says obstetrician and gynecologist Rebecka Kaplan Sturk.